Literature DB >> 21684615

Altering the expression balance of hnRNP C1 and C2 changes the expression of myelination-related genes.

Keiko Iwata1, Hideo Matsuzaki, Takayuki Manabe, Norio Mori.   

Abstract

The expression level of hnRNP C1/C2 protein has been reported to be significantly decreased in the post-mortem brain of schizophrenic patients. In this study, we investigated whether overexpression of the hnRNP C variants hnRNP C1 and C2 changed the expression of myelination-related genes in the human neuroblastoma cell line SK-N-SH. In both hnRNP C1- and C2-overexpressing cells, the expression of quaking (QKI)-6 and QKI-7 significantly increased or decreased compared to the control, respectively. Intriguingly, QKI-5 and myelin basic protein were markedly up- or down-regulated by overexpressing hnRNP C2, respectively. Our findings are the first to demonstrate distinct functions of hnRNP C1 and C2, and may be helpful in understanding the functions of these molecules. These findings indicate that altered expression levels of hnRNP C in the brain of patients with schizophrenia could be involved in the pathophysiology of this disease through alteration of the QKI isoform and myelin basic protein expression.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684615     DOI: 10.1016/j.psychres.2011.05.043

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Gene expression in superior temporal cortex of schizophrenia patients.

Authors:  C Sellmann; L Villarín Pildaín; A Schmitt; F Leonardi-Essmann; P F Durrenberger; R Spanagel; T Arzberger; H Kretzschmar; M Zink; O Gruber; M Herrera-Marschitz; R Reynolds; P Falkai; P J Gebicke-Haerter; F Matthäus
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11-28       Impact factor: 5.270

2.  The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains.

Authors:  Verônica M Saia-Cereda; Aline G Santana; Andrea Schmitt; Peter Falkai; Daniel Martins-de-Souza
Journal:  Mol Neuropsychiatry       Date:  2017-06-17

3.  Variant in NHLRC2 leads to increased hnRNP C2 in developing neurons and the hippocampus of a mouse model of FINCA disease.

Authors:  Anniina E Hiltunen; Salla M Kangas; Steffen Ohlmeier; Ilkka Pietilä; Jori Hiltunen; Heikki Tanila; Colin McKerlie; Subashika Govindan; Hannu Tuominen; Riitta Kaarteenaho; Mikko Hallman; Johanna Uusimaa; Reetta Hinttala
Journal:  Mol Med       Date:  2020-12-09       Impact factor: 6.354

4.  Control of CNS functions by RNA-binding proteins in neurological diseases.

Authors:  Yijing Zhou; Fengping Dong; Yingwei Mao
Journal:  Curr Pharmacol Rep       Date:  2018-05-02

5.  Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes.

Authors:  Giuliana S Zuccoli; Guilherme Reis-de-Oliveira; Bruna Garbes; Peter Falkai; Andrea Schmitt; Helder I Nakaya; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-03-10       Impact factor: 5.270

6.  Developmental splicing deregulation in leukodystrophies related to EIF2B mutations.

Authors:  Aurélia Huyghe; Laetitia Horzinski; Alain Hénaut; Marina Gaillard; Enrico Bertini; Raphael Schiffmann; Diana Rodriguez; Yann Dantal; Odile Boespflug-Tanguy; Anne Fogli
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

7.  Gene expression profiling of the dorsolateral and medial orbitofrontal cortex in schizophrenia.

Authors:  Mihovil Mladinov; Goran Sedmak; Heidi R Fuller; Mirjana Babić Leko; Davor Mayer; Jason Kirincich; Andrija Štajduhar; Fran Borovečki; Patrick R Hof; Goran Šimić
Journal:  Transl Neurosci       Date:  2016-11-27       Impact factor: 1.757

8.  Biochemical Pathways Triggered by Antipsychotics in Human [corrected] Oligodendrocytes: Potential of Discovering New Treatment Targets.

Authors:  Caroline Brandão-Teles; Valéria de Almeida; Juliana S Cassoli; Daniel Martins-de-Souza
Journal:  Front Pharmacol       Date:  2019-03-05       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.